News Daily News MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission Todd Neale December 29, 2021
News Daily News AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD Caitlin E. Cox December 28, 2021
News Daily News Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study Todd Neale December 27, 2021
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Daily News Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions L.A. McKeown December 17, 2021
News Daily News Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation Todd Neale November 25, 2021
News Daily News Predictors of AF May Help Guide Care After Stroke of Unknown Cause Caitlin E. Cox October 26, 2021
News Daily News ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients Todd Neale October 13, 2021
News Daily News HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients Yael L. Maxwell October 12, 2021
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Daily News Women Stand to Gain the Most From Standardized STEMI Protocols Michael O'Riordan September 30, 2021
News Daily News Score May Help Guide VITT Management After COVID-19 Vaccination Todd Neale September 23, 2021
News Daily News Long-term Anticoagulation After Unprovoked VTE: New Insights Shelley Wood September 13, 2021
News Daily News Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data Caitlin E. Cox August 16, 2021
News Daily News Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features Todd Neale August 11, 2021
News Daily News Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t Shelley Wood August 04, 2021